Reslizumab | 合法藥品大搜索

Reslizumabisaninterleukin-5antagonistmonoclonalantibody.IL-5isthemajorcytokineresponsibleforthegrowthanddifferentiation,recruitment,activation,and ...,WhatisCINQAIR?CINQAIRisaprescriptionmedicineusedwithotherasthmamedicinesforthemaintenancetreatmentofasthmainpeopleaged18yearsofage ...,由SHom著作·2017·被引用18次—ReslizumabisanIL-5antagonist(immunoglobulinG4-kappa).IL-5isamajorcytokineinvolvedinthegrowth,differentiation,recruitment,activation,andsurvivalof ...,Medscape-AsthmadosingforCinqair(r...

reslizumab asthma Benralizumab reslizumab mechanism of action reslizumab vs mepolizumab reslizumab covid reslizumab injection Mepolizumab reslizumab uses reslizumab台灣 Reslizumab reslizumab dose reslizumab cost Benralizumab benralizumab仿單 mepolizumab機轉 mepolizumab健保 mepolizumab仿單 benralizumab健保 Mepolizumab mepolizumab中文 reslizumab asthma reslizumab mechanism of action reslizumab vs mepolizumab reslizumab covid reslizumab injection reslizumab uses reslizumab台灣 Reslizumab reslizumab dose reslizumab cost Reslizumab trial reslizumab subcutaneous Dupilumab nejm Dupilumab asthma reslizumab cost in india benralizumab cost mepolizumab cost nct01285323 cinqair fasenra cinqair price reslizumab side effects dupilumab cinqaero (reslizumab) reslizumab indication Reslizumab fda Benralizumab FDA NUCALA injection FASENRA injection benralizumab benralizumab mechanism of action dupilumab mechanism of action omalizumab mechanism of action benralizumab brand name what is benralizumab Dupilumab CINQAIR dupilumab vs mepolizumab Mepolizumab benralizumab benralizumab vs dupilumab benralizumab vs omalizumab nucala vs fasenra vs dupixent benralizumab review xolair and dupixent combination EAACI biologicals Guidelines recommendations for severe asthma 氣喘治療指引2020 氣喘治療指引2019 氣喘指引2020 氣喘治療指引2021 台灣氣喘人數 gina氣喘2020 氣喘嚴重度分級台灣氣喘治療指引胰妥讚哪裡買維他命h ptt propranolol抗焦慮高血脂危險因子 ”愛您美”消痘乳膏0.5公絲/公克副作用糖尿藥副作用 Cyproheptadine 速佑寶止痛軟膠囊頭痛

Reslizumab | 合法藥品大搜索

Reslizumab is an interleukin-5 antagonist monoclonal antibody. IL-5 is the major cytokine responsible for the growth and differentiation, recruitment, activation, and ... Read More

CINQAIR® (reslizumab) Injection | 合法藥品大搜索

What is CINQAIR? CINQAIR is a prescription medicine used with other asthma medicines for the maintenance treatment of asthma in people aged 18 years of age ... Read More

Reslizumab (Cinqair) | 合法藥品大搜索

由 S Hom 著作 · 2017 · 被引用 18 次 — Reslizumab is an IL-5 antagonist (immunoglobulin G4-kappa). IL-5 is a major cytokine involved in the growth, differentiation, recruitment, activation, and survival of ... Read More

Cinqair (reslizumab) dosing, indications | 合法藥品大搜索

Medscape - Asthma dosing for Cinqair (reslizumab), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy & lactation ... Read More

The effectiveness of Reslizumab in severe asthma treatment ... | 合法藥品大搜索

由 H Ibrahim 著作 · 2019 · 被引用 14 次 — Reslizumab is a humanized monoclonal antibody directed against Interleukin-5. It binds specifically to IL-5 thereby blocking its biological effects ... Read More

Reslizumab for inadequately controlled asthma with elevated ... | 合法藥品大搜索

由 M Castro 著作 · 2015 · 被引用 874 次 — Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, ... Read More

Reslizumab in patients with inadequately controlled late | 合法藥品大搜索

由 G Brusselle 著作 · 2017 · 被引用 85 次 — Compared with placebo, reslizumab produced larger reductions in asthma exacerbations and larger improvements in lung function in patients ... Read More

Reslizumab | 合法藥品大搜索

Reslizumab is a humanized, IgG4κ monoclonal antibody that inhibits IL-5 binding to the α-subunit of the IL-5 receptor complex on the eosinophil. In contrast to ... Read More

CINQAERO, INN-reslizumab | 合法藥品大搜索

Effect on sputum eosinophils. The effect of reslizumab in patients with asthma and elevated sputum eosinophil counts (at least 3%) was evaluated in a 15-week, ... Read More

相關資訊整理